
Ionis Pharmaceuticals Partner Biogen Reports Positive Phase 2 Results for Diranersen in Early Alzheimer’s Disease
Ionis and Biogen Report Promising Phase 2 Results for Tau-Targeting Alzheimer’s Therapy Diranersen Ionis Pharmaceuticals and Biogen have announced encouraging topline findings from the Phase 2 CELIA clinical study evaluating diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) therapy designed to…












